atrasentan
Sign in to saveAlso known as A-127722, A-147627, ABT-627
Atrasentan, sold under the brand name Vanrafia, is a medication used to reduce proteinuria. It is an endothelin receptor antagonist. It is taken by mouth.
Research
510 papers- Atrasentan in Patients with IgA Nephropathy.The New England journal of medicine · 2025
- Atrasentan: First Approval.Drugs · 2025
- Atrasentan.2006
- Atrasentan.2012
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.Lancet (London, England) · 2019
via PubMed
~2 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Society and culture
- Legal status
- Names
- Research
- Clinical trials
- See also
- References
- External links
Atrasentan, sold under the brand name Vanrafia, is a medication used to reduce proteinuria. It is an endothelin receptor antagonist. It is taken by mouth.
Atrasentan was approved for medical use in the United States for IgA nephropathy in April 2025.
Excerpted from Wikipedia’s “atrasentan” article, available under the CC BY-SA 4.0 licence.